Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02697474 | Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. | PHASE3 | COMPLETED | 150 | — | — | Feb 1, 2016 | Jan 1, 2017 | Apr 6, 2022 | 2 | Thailand |
| Arm | Type | Description |
|---|---|---|
| Hexaxim® Group | EXPERIMENTAL | Subjects that received Hexaxim® in Study A3L12 |
| Infanrix® hexa Group | EXPERIMENTAL | Subjects that received Infanrix® hexa in Study A3L12 |
| Name | Type | Description |
|---|---|---|
| Euvax B®: Hepatitis B vaccine | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Informed consent form signed by subject's parent/legally acceptable representative * Assent form signed by subject * Subject and parent(s)/legally acceptable representatives able to attend the scheduled visits and to comply with all trial procedures * Receipt of primary vaccin...